Sir, Exposure to verteporfin and bevacizumab therapy for choroidal neovascularization secondary to punctate inner choroidopathy during pregnancy A pregnant woman diagnosed with choroidal neovascularization (CNV) secondary to punctate inner choroidopathy was treated with verteporfin and bevacizumab, without fetal side effects.
A 24-year-old healthy myope presented with blurred vision in her right eye, with a visual acuity (VA) of 20/40 in the right eye and 20/25 in the left. Funduscopic findings revealed peripapillary chorioretinal plaques bilaterally, and an elevated grey subfoveal lesion RE. Fluorescein angiography confirmed right eye CNV and multiple punctate peripapillary and midperipheral hyperfluorescences.
After explaining the treatment options, she underwent PDT. Twelve days later, we were informed that bHCG levels and an ultrasound were consistent with a fourth week pregnancy, indicating exposure to PDT 1-to 2-week postconception. The patient was informed of possible risks related to her drug exposure.
Subsequently, right eye VA decreased to 20/70, and a thickened CNV was evident on FA with subfoveal fluid on OCT. After discussing treatment options, she underwent intravitreal injection of 1.25 mg bevacizumab (Avastin, Genentech, San Francisco, CA, USA) 3-month postconception. VA improved to 20/30, the macular lesion became a small atrophic scar, with stable OCT scans and VA throughout follow-up, until 3-month postpartum.
The pregnancy continued under observation. Two fetal ultrasounds were normal, and she delivered a healthy infant at term, without congenital anomalies then or at a 3-month follow-up examination.
A teratogenic effect of verteporfin exposure was found in rat fetuses at 40-125 times the human dose. 1 The risk of fetal exposure to activated verteporfin is smaller, and it is also not exposed to activating light. De Santis et al 2 reported verteporfin exposure in the first week postconception in a woman who had a healthy child.
Systemic bevacizumab is teratogenic in rabbits in doses twice the recommended intravenous human dose. 1 Our patient was exposed to intravitreal bevacizumab during the second trimester. Data from Genentech concerning ranibizumab (B50 kD) revealed unmeasurable serum concentrations following intravitreal administration. This is expected to be even lower for the higher molecular weight bevacizumab. Nevertheless, minimal systemic absorption should be suspected, and although the drug could not cross the placenta barrier due to its high molecular weight (B149 kD), a theoretical effect on placental vaculature was kept in mind.
